Overview and Scope
Bronchodilators are a type of medication that makes breathing easier by relaxing the muscles in the lungs and widening the airways (bronchi). They are often used to treat long-term conditions where the airways may become narrow and inflamed, such as asthma and chronic obstructive pulmonary disease (COPD).
Sizing and Forecast
The bronchodilators market size has grown strongly in recent years. It will grow from $30.43 billion in 2023 to $32.93 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to growing geriatric population, rising incidence of asthma, growing funding by government organizations, increase in ageing population, and increasing air pollution across the globe.
The bronchodilators market size is expected to see strong growth in the next few years. It will grow to $43.25 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to increasing prevalence of COPD, rising awareness about lung diseases treatment aided with escalating research and development efforts, increase in prevalence of pulmonary disorders, the rise in disposable income, and increasing smoking rates. Major trends in the forecast period include advanced clinical research and innovative strategies, growing technological advancements, high prevalence of lung diseases such as COPD and asthma, new product launches, and rising number of patients with acute respiratory infections.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/bronchodilators-global-market-report
Segmentation & Regional Insights
The bronchodilators market covered in this report is segmented –
1) By Type: Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Xanthine Derivatives, Other Types
2) By Route of Administration: Oral, Nasal (Inhalation), Injectable
3) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Reactions, Breathing Problem, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Other End Users
North America was the largest region in the bronchodilators market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchodilators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13816&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel the growth of the bronchodilator market going forward. Chronic obstructive pulmonary disease is a progressive lung disease characterized by chronic inflammation of the airways and obstruction or limitation of airflow. Bronchodilators are used in chronic obstructive pulmonary disease (COPD) to relax the muscles around the airways, which helps to open the airways and make it easier to breathe. For instance, in March 2023, according to a report by the Scottish Public Health Observatory, led by Public Health Scotland, a UK-based Population Health Centre, COPD rates started to increase as the impact of COVID-19 eased. The rate in males increased from 83.2 to 97.6 cases per 100,000, and for females, the increase was from 72.6 to 97.3. Therefore, the increasing prevalence of chronic obstructive pulmonary disease (COPD) is driving the growth of the bronchodilator market.
Key Industry Players
Major companies operating in the bronchodilators market report are Pfizer Inc. , Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Thermo Fisher Scientific, Abbott Laboratories , Sanofi S.A., GlaxoSmithKline plc, Siemens Healthcare GmbH, Merck & Co. Inc., AstraZeneca plc, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Quest Diagnostics Incorporated., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Bio-Rad Laboratories Inc., Cipla Limited, Hikma Pharmaceutical plc, Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, Vectura Group Limited, Foundation Medicine Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., Kissei Pharmaceutical Co.Ltd., Mitsubishi Tanabe Pharma, Theron Pharmaceuticals, Viatris Inc.
The bronchodilators market report table of contents includes:
1. Executive Summary
- Bronchodilators Market Characteristics
- Bronchodilators Market Trends And Strategies
- Bronchodilators Market – Macro Economic Scenario
- Global Bronchodilators Market Size and Growth
.
32. Global Bronchodilators Market Competitive Benchmarking - Global Bronchodilators Market Competitive Dashboard
- Key Mergers And Acquisitions In The Bronchodilators Market
- Bronchodilators Market Future Outlook and Potential Analysis
- Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
